ERYTech Pharma SA Sponsored ADR

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

PRESS RELEASE P HAXIAM Therapeutics announces a reverse share split of its shares Reverse share split by the exchange of ten (10) existing shares with a par value of ten-euro cents (€0.10) for one (1) new share with a par value of one euro (€1) Publication of the reverse share split notice in the BALO: July 31 st , 2023 Start of the reverse share split: August 16 th , 2023 Effective date of the reverse share split (listing of new shares): September  18 th , 2023 Lyon (France) and Cambridge (MA, US) , July 2 7 th , 2023 - P HAXIAM Therapeutics (Nasdaq & Euronext: PHXM ) (the "Company") , today announces the implementation of the reverse share split of the shares composing the Company's share capital, by de cision of the Chief Executive Officer on July 2 7 th , 2023 , following the sub-delegation granted by the Board of Directors on June 23 rd , 2023, taken in accordance with the twenty-third extraordinary resolution of the General Shareholders ' Meeting of June 23 rd , 2023 . REVERSE SHAR E SPLIT OF THE COMPANY'S SHARES The reverse share split will result in the exchange of ten (10) existing shares with a par value of ten-euro cents (€0.10) (the "Existing Shares") for one (1) new share with a par value of one euro (€1) (a "New Share").

PHAXIAM Therapeutics announces a reverse share split of its shares

Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135), announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and will be effective from June 29, 2023.

Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM

ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics Merger approved with large majority by the shareholders of both companies New governance structure implemented Ambition to create a global leader in extended phage therapies to target antimicrobial resistant pathogenic bacteria Lyon (France) and Cambridge (MA, US), June 26, 2023 – ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR). “In February this year, we announced our strategic plans with PHERECYDES, with the intent to build a global leader in phage therapy and address the huge medical need caused by antimicrobial resistance.

ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor, including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023.

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder's Meeting held on June 23, 2023

Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners.

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

Cambridge, MA (U.S.) and Lyon (France), June 14, 2023, 8:00 pm CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced today that the Lyon Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma.

ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma

Cambridge, MA (U.S.) and Lyon (France), June 12, 2023, 7:00 am CEST – ERYTECH Pharma (Nasdaq & Euronext: ERYP), today reacts to a series of disinformation attempts by Akkadian Partners to try and destabilize ERYTECH.

ERYTECH Responds to Akkadian's Disinformation

ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

Cambridge, MA (U.S.) and Lyon (France), May 24, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 23, 2023.

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023

ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes. Lyon (France), May 23, 2023 - ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has published the exemption document relating to the proposed combination with Pherecydes.

ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes

ERYTECH Provides Update on the Announced Combination with PHERECYDES

Erytech Pharma SA (NASDAQ:ERYP ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Gil Beyen - CEO Thibaut du Fayet - CEO, Pherecydes Pharma Didier Hoch - Chairman, Pherecydes Pharma Conference Call Participants Jacob Mekhael - Kempen & Co. Operator Thank you for standing by, and welcome to the conference call on the proposed merger between ERYTECH Pharma and Pherecydes Pharma. [Operator Instructions].

Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript

Erytech Pharma (NASDAQ: ERYP ) stock is on the rise Tuesday after the company provided investors with a business update for Q1! First up is the company's planned merger with Pherecydes.

Why Is Erytech Pharma (ERYP) Stock Up 47% Today?

ERYTECH Provides Business and Financial Update for the First Quarter of 2023

Cambridge, MA (U.S.) and Lyon (France), April 17, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received approval from The Nasdaq Stock Market LLC ("Nasdaq") dated April 12, 2023, to transfer the listing of its American Depositary Shares representing ordinary shares of the Company (“ADSs”) from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer became effective at the opening of business on April 14, 2023.

ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market

Combination with Pherecydes announced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies

ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies

ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q3 2022 Earnings Conference Call November 22, 2022 8:30 AM ET Company Participants Gil Beyen - CEO Eric Soyer - CFO and COO Conference Call Participants Boris Peaker - Cowen Operator Good morning, and thank you for standing by.

ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript

Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC ("Nasdaq") dated October 7, 2022, indicating that, based upon a closing bid price of less than $1.00 per share for the Company's American Depositary Shares (“ADSs”) for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5450(a)(1).

ERYTECH Announces Receipt of Nasdaq Notice

Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why

ERYTECH Pharma S.A. (NASDAQ:ERYP ) Q2 2022 Results Conference Call September 13, 2022 8:30 AM ET Company Participants Gil Beyen - Chief Executive Officer Eric Soyer - Chief Financial and Chief Operating Officer Dr. Iman El-Hariry - Chief Medical Officer Conference Call Participants Jacob Mekhael - Kempen Operator Good day, and thank you for standing by.

ERYTECH Pharma S.A. (ERYP) Q2 2022 Earnings Call Transcript

ERYTECH Provides Business and Financial Update for the First Half of 20 2 2

ERYTECH Provides Business and Financial Update for the First Half of 2022

After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.

Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%

Cambridge, MA (U.S.) and Lyon (France), August 24, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia (ALL) following feedback from the U.S. Food and Drug Administration (FDA).

ERYTECH Provides Regulatory Update

REPORT – ERYTECH 'S COMBINED SHAREHOLDERS' MEETING ON JUNE 2 4 , 20 22

News for ERYTech Pharma SA Sponsored ADR Stock (ERYP)